TM7SF3

Across TCGA pan-cancer cohorts, TM7SF3 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TM7SF3 data layer compared with 19 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher TM7SF3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TM7SF3 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUSC, PRAD, and LIHC are the cancer types where TM7SF3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	All	0.234	0.750	.001	18	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LIHC	DFS	Median	II,III,IV	0.083	0.427	.028	6	view →
LUAD	OS	Median	All	0.336	0.685	.033	3	view →
UCEC	DFS	Median	All	0.973	0.829	.031	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TM7SF3–LUSC (DFS)

Open the LUSC breakdown →